Drugs / BL-1021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01121380 | Jun → Oct 2011 | — | BioLineRx, Ltd. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2011-12-06 | BioLineRx, Ltd. | Results BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain biolinerx.com ↗
BioLineRx (NASDAQ:BLRX) (TASE:BLRX) announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain. |
| 2011-09-13 | BioLineRx, Ltd. | Results BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain biolinerx.com ↗
Study results demonstrated that a single administration of BL-1021 was safe and well tolerated. |
| 2010-08-30 | BioLineRx, Ltd. | Results BioLineRx presents data on BL-1021, a New Chemical Entity for treatment of neuropathic pain, at 13th World Congress on Pain, Montreal, Canada biolinerx.com ↗
In vivo experiments conducted with BL-1021 have demonstrated the efficacy of a single administration of BL-1021 in the Chung model of neuropathic pain. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01121380 ↗ |
| Modality | Small molecule | “BL-1021 is an orally available NCE” NCT01121380 ↗ |
| Route | Oral | “BL-1021 is an orally available NCE” NCT01121380 ↗ |